Navigation Links
Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved

STOCKHOLM, March 4 /PRNewswire-FirstCall/ -- Diamyd Medical announces today that the Swedish Medical Products Agency has approved a study with the Diamyd(R) diabetes vaccine in children with high risk to develop type 1 diabetes.

(Logo: )

"To vaccinate children against diabetes has from the outset been one of Diamyd Medical's long term goals," says Elisabeth Lindner, President and CEO of Diamyd Medical. "Type 1 diabetes is a life-long and very serious disease and it is good if we now can prevent it. It would avoid a lot of anxiety, suffering and costs for the children and their families as well as the rest of Society."

At Malmo University Hospital in Sweden, large screening tests results in a continuous identification of children that are subject to a very high risk of developing type 1 diabetes. By measuring different biomarkers in blood samples, it is possible to determine in an early stage that these children are in the autoimmune disease process that destroys their insulin producing cells.

If vaccination with Diamyd(R) succeeds to intervene in the disease process before too many of the insulin cells are destroyed, the disease will be prevented. The child would then escape diabetes symptoms and would not become dependent on insulin injections for survival, which otherwise is unavoidable.

"We meet with these kids every third month and we know that virtually all of them will present with type 1 diabetes. Many of us pediatricians have been frustrated not to be able to interfere. But now, and I have to admit it feels almost a bit unreal, we may for the first time have a real opportunity to save these children from the disease," says Helena Elding Larsson, pediatrician from Malmo and researcher at Lund University in Sweden.

The approved study comprises, under the present approval, up to 50 children from 4 years of age who are known to have a high risk of developing type 1 diabetes. The study will be randomized and placebo controlled.

This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.

    Diamyd Medical AB (publ.)
    Linnegatan 89 B, SE-115 23 Stockholm, Sweden
    Phone: +46-8-661-00-26,
    Fax: +46-8-661-63-68

    VATno: SE556530-142001. ticker: DIAM B; ticker: DMYDY)

SOURCE Diamyd Medical AB (publ)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Diamyd(R) Study Published in Prestigious New England Journal of Medicine
2. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
3. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
4. TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
5. Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
6. Laser Burn Injuries in One Eye Can Disrupt Protective Immune Privilege in Both Eyes, Study Finds
7. Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmers Trabecular Metal(TM) Technology
8. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
9. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia
10. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
11. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
Post Your Comments:
(Date:10/13/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... Therapy Catapult to advance development of large scale ... immunotherapy. Under the agreement, the Cell Therapy Catapult ... to support advanced clinical trials and eventual commercialization ... --> The Cell Therapy Catapult is a ...
(Date:10/12/2015)... WASHINGTON , Oct. 12, 2015  Former White House ... Press Secretary for the House Narcotics Committee, Robert Weiner ... "Rewriting Drug Policy." The two emphasize that this is now ... Clinton to Jeb Bush , Carly Fiorina ... Sordello cite the newest federal statistics, which they call "a ...
(Date:10/12/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and the Dental sectors of healthcare, announced today ... 2015, its guidance for the fourth quarter of 2015, ... Senior Secured Credit Facility. --> ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Doulagivers is O'Brien's licensed ... and End of Life Doula Training. A Doulagiver is a non-medical person ... emotionally. Based on her #1 International bestselling book Creating Positive Passings & ...
(Date:10/12/2015)... SOUTH BELOIT, IL (PRWEB) , ... October 13, 2015 , ... ... Industrial Buyers Consortium (IBC) at the 2015 IBC National Meeting in Rosemont, IL on ... best represent the dedication, quality, and standards of excellence that customers have come to ...
(Date:10/12/2015)... ... October 12, 2015 , ... According to an article ... athletes, particularly in the area of track and field, are at a significantly ... male peers in the same age group. Dr. Steven Meier of Meier Orthopedic ...
(Date:10/12/2015)... Illinois (PRWEB) , ... October 12, 2015 , ... ... support the practice of hypnosis by individuals who lack professional education and clinical ... hypnosis to the public for a variety of purposes such as: losing weight, ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Horizon Foundation for New Jersey has awarded ... health and enhancing the quality of life in the Garden State. The grants, representing ... organizations. , The charitable arm of Horizon Blue Cross Blue Shield of New ...
Breaking Medicine News(10 mins):